Search | OpenScholar

Search results

1934 results found

Substantial improvement in a Meige's syndrome patient with levetiracetam treatment. Movement Disorders 2004;19:1518-1521.

Publication: Journal Article

Zesiewicz, TA, ED Louis, KL Sullivan, M Menkin, PB Dunne, and RA Hauser. 2004. “Substantial Improvement in a Meige’s Syndrome Patient With Levetiracetam Treatment. Movement Disorders 2004;19:1518-1521.”. Movement Disorders.

Essential tremor. Epidemiology, diagnosis, and treatment. Neurologist 2004;10:250-258.

Publication: Journal Article

Sullivan, KL, RA Hauser, and TA Zesiewicz. 2004. “Essential Tremor. Epidemiology, Diagnosis, and Treatment. Neurologist 2004;10:250-258.”. Neurologist.

Double-blinded, placebo-controlled study of entacapone in levodopa-treated patients with Parkinson disease. Archives of neurology, 61(10), 1563.

Publication: Journal Article

Olanow, CW, K Kieburtz, M Stern, R Watts, JW Langston, M Guarnieri, RA Hauser, and J Hubble. 2004. “Double-Blinded, Placebo-Controlled Study of Entacapone in Levodopa-Treated Patients With Parkinson Disease. Archives of Neurology, 61(10), 1563.”. Archives of Neurology.

Autonomic nervous system dysfunction in Parkinson’s disease. Curr Treat Options Neurol 2003; 5:149-160.

Publication: Journal Article

Zesiewicz, TA, MJ Baker, M Wahba, and RA Hauser. 2003. “Autonomic Nervous System Dysfunction in Parkinson’s Disease. Curr Treat Options Neurol 2003; 5:149-160.”. Curr Treat Options Neurol.

Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson’s disease.

Publication: Journal Article

Kase, H, S Aoyama, M Ichimura, K Ikeda, A Ishii, T Kanda, K Koga, and . 2003. “Progress in Pursuit of Therapeutic A2A Antagonists: the Adenosine A2A Receptor Selective Antagonist KW6002: Research and Development Toward a Novel Nondopaminergic Therapy for Parkinson’s Disease.”. Neurology.

Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303.

Publication: Journal Article

Hauser, RA, JP Hubble, and DD Truong. 2003. “Randomized Trial of the Adenosine A2A Receptor Antagonist Istradefylline in Advanced PD. Neurology 2003;61:297-303.”. Neurology.

Driving safety in Parkinson’s disease. Neurology 2002;59:1787-1788.

Publication: Journal Article

Zesiewicz, TA, CR Cimino, AR Malek, N Gardner, PL Leaverton, PB Dunne, and RA Hauser. 2002. “Driving Safety in Parkinson’s Disease. Neurology 2002;59:1787-1788.”. Neurology.

Hyaluronic acid (HA)-Gd(III) and HA-Fe(III) microgels as MRI contrast enhancing agents

Publication: Journal Article

Sahiner, Nurettin, Evrim Umut, Selin S. Suner, Mehtap Sahiner, Mustafa Culha, and Ramesh S. Ayyala. 2022. “Hyaluronic Acid (HA)-Gd(III) and HA-Fe(III) Microgels As MRI Contrast Enhancing Agents”. Carbohydrate Polymers 277: 118873.

Mesoporous, degradable hyaluronic acid microparticles for sustainable drug delivery application

Publication: Journal Article

Sahiner, Nurettin ", Selin S Suner, and Ramesh S" Ayyala. 2019. “Mesoporous, Degradable Hyaluronic Acid Microparticles for Sustainable Drug Delivery Application”. Colloids Surf. B Biointerfaces 177: 284-93.

Polyethyleneimine modified poly(Hyaluronic acid) particles with controllable antimicrobial and anticancer effects

Publication: Journal Article

Sahiner, Nurettin ", Selin Sagbas, Mehtap and Sahiner, and Ramesh S Ayyala. 2017. “Polyethyleneimine Modified Poly(Hyaluronic Acid) Particles With Controllable Antimicrobial and Anticancer Effects”. Carbohydr. Polym. 159: 29-38.